Cargando…

CRISPR-Cas systems for diagnosing infectious diseases

Infectious diseases are a global health problem affecting billions of people. Developing rapid and sensitive diagnostic tools is key for successful patient management and curbing disease spread. Currently available diagnostics are very specific and sensitive but time-consuming and require expensive...

Descripción completa

Detalles Bibliográficos
Autores principales: Kostyusheva, Anastasiya, Brezgin, Sergey, Babin, Yurii, Vasilyeva, Irina, Glebe, Dieter, Kostyushev, Dmitry, Chulanov, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032595/
https://www.ncbi.nlm.nih.gov/pubmed/33839288
http://dx.doi.org/10.1016/j.ymeth.2021.04.007
_version_ 1783676240138338304
author Kostyusheva, Anastasiya
Brezgin, Sergey
Babin, Yurii
Vasilyeva, Irina
Glebe, Dieter
Kostyushev, Dmitry
Chulanov, Vladimir
author_facet Kostyusheva, Anastasiya
Brezgin, Sergey
Babin, Yurii
Vasilyeva, Irina
Glebe, Dieter
Kostyushev, Dmitry
Chulanov, Vladimir
author_sort Kostyusheva, Anastasiya
collection PubMed
description Infectious diseases are a global health problem affecting billions of people. Developing rapid and sensitive diagnostic tools is key for successful patient management and curbing disease spread. Currently available diagnostics are very specific and sensitive but time-consuming and require expensive laboratory settings and well-trained personnel; thus, they are not available in resource-limited areas, for the purposes of large-scale screenings and in case of outbreaks and epidemics. Developing new, rapid, and affordable point-of-care diagnostic assays is urgently needed. This review focuses on CRISPR-based technologies and their perspectives to become platforms for point-of-care nucleic acid detection methods and as deployable diagnostic platforms that could help to identify and curb outbreaks and emerging epidemics. We describe the mechanisms and function of different classes and types of CRISPR-Cas systems, including pros and cons for developing molecular diagnostic tests and applications of each type to detect a wide range of infectious agents. Many Cas proteins (Cas3, Cas9, Cas12, Cas13, Cas14 etc.) have been leveraged to create highly accurate and sensitive diagnostic tools combined with technologies of signal amplification and fluorescent, potentiometric, colorimetric, lateral flow assay detection and other. In particular, the most advanced platforms -- SHERLOCK/v2, DETECTR, CARMEN or CRISPR-Chip -- enable detection of attomolar amounts of pathogenic nucleic acids with specificity comparable to that of PCR but with minimal technical settings. Further developing CRISPR-based diagnostic tools promises to dramatically transform molecular diagnostics, making them easily affordable and accessible virtually anywhere in the world. The burden of socially significant diseases, frequent outbreaks, recent epidemics (MERS, SARS and the ongoing COVID-19) and outbreaks of zoonotic viruses (African Swine Fever Virus etc.) urgently need the developing and distribution of express-diagnostic tools. Recently devised CRISPR-technologies represent the unprecedented opportunity to reshape epidemiological surveillance and molecular diagnostics.
format Online
Article
Text
id pubmed-8032595
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-80325952021-04-09 CRISPR-Cas systems for diagnosing infectious diseases Kostyusheva, Anastasiya Brezgin, Sergey Babin, Yurii Vasilyeva, Irina Glebe, Dieter Kostyushev, Dmitry Chulanov, Vladimir Methods Article Infectious diseases are a global health problem affecting billions of people. Developing rapid and sensitive diagnostic tools is key for successful patient management and curbing disease spread. Currently available diagnostics are very specific and sensitive but time-consuming and require expensive laboratory settings and well-trained personnel; thus, they are not available in resource-limited areas, for the purposes of large-scale screenings and in case of outbreaks and epidemics. Developing new, rapid, and affordable point-of-care diagnostic assays is urgently needed. This review focuses on CRISPR-based technologies and their perspectives to become platforms for point-of-care nucleic acid detection methods and as deployable diagnostic platforms that could help to identify and curb outbreaks and emerging epidemics. We describe the mechanisms and function of different classes and types of CRISPR-Cas systems, including pros and cons for developing molecular diagnostic tests and applications of each type to detect a wide range of infectious agents. Many Cas proteins (Cas3, Cas9, Cas12, Cas13, Cas14 etc.) have been leveraged to create highly accurate and sensitive diagnostic tools combined with technologies of signal amplification and fluorescent, potentiometric, colorimetric, lateral flow assay detection and other. In particular, the most advanced platforms -- SHERLOCK/v2, DETECTR, CARMEN or CRISPR-Chip -- enable detection of attomolar amounts of pathogenic nucleic acids with specificity comparable to that of PCR but with minimal technical settings. Further developing CRISPR-based diagnostic tools promises to dramatically transform molecular diagnostics, making them easily affordable and accessible virtually anywhere in the world. The burden of socially significant diseases, frequent outbreaks, recent epidemics (MERS, SARS and the ongoing COVID-19) and outbreaks of zoonotic viruses (African Swine Fever Virus etc.) urgently need the developing and distribution of express-diagnostic tools. Recently devised CRISPR-technologies represent the unprecedented opportunity to reshape epidemiological surveillance and molecular diagnostics. Elsevier Inc. 2022-07 2021-04-09 /pmc/articles/PMC8032595/ /pubmed/33839288 http://dx.doi.org/10.1016/j.ymeth.2021.04.007 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Kostyusheva, Anastasiya
Brezgin, Sergey
Babin, Yurii
Vasilyeva, Irina
Glebe, Dieter
Kostyushev, Dmitry
Chulanov, Vladimir
CRISPR-Cas systems for diagnosing infectious diseases
title CRISPR-Cas systems for diagnosing infectious diseases
title_full CRISPR-Cas systems for diagnosing infectious diseases
title_fullStr CRISPR-Cas systems for diagnosing infectious diseases
title_full_unstemmed CRISPR-Cas systems for diagnosing infectious diseases
title_short CRISPR-Cas systems for diagnosing infectious diseases
title_sort crispr-cas systems for diagnosing infectious diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032595/
https://www.ncbi.nlm.nih.gov/pubmed/33839288
http://dx.doi.org/10.1016/j.ymeth.2021.04.007
work_keys_str_mv AT kostyushevaanastasiya crisprcassystemsfordiagnosinginfectiousdiseases
AT brezginsergey crisprcassystemsfordiagnosinginfectiousdiseases
AT babinyurii crisprcassystemsfordiagnosinginfectiousdiseases
AT vasilyevairina crisprcassystemsfordiagnosinginfectiousdiseases
AT glebedieter crisprcassystemsfordiagnosinginfectiousdiseases
AT kostyushevdmitry crisprcassystemsfordiagnosinginfectiousdiseases
AT chulanovvladimir crisprcassystemsfordiagnosinginfectiousdiseases